IMPROVING PATIENT SAFETY AND OUTCOMES: EU-HYPROTECT REGISTRY DEMONSTRATES REDUCED TIME IN HYPOTENSION DURING SURGERY USING ACUMEN HPI SOFTWARE

• In Europe, of the 2.5 million patients undergoing high-risk surgery annually, one in four develops serious postoperative complications.^1,2
• Intraoperative hypotension (critical drops in blood pressure during surgery) is associated with mortality and major postoperative complications (myocardial injury, acute kidney injury).^(3-8)
• EU-HYPROTECT, a European multicenter prospective observational registry which included in its final analysis 702 non-cardiac surgical patients of 12 centers, demonstrates a low rate of hypotension during surgery with the use of the Acumen Hypotension Prediction Index (HPI) software, a monitoring system that predicts hypotension and alerts clinicians before a drop in blood pressure happens.

NYON (SWITZERLAND), June 8^th, 2023 – Edwards Lifesciences today announced the results of the EU-HYPROTECT registry which indicates that using Acumen HPI software may help reduce the duration and severity of intraoperative hypotension in patients having non-cardiac surgery.

EU-HYPROTECT is a European multicenter prospective observational registry which included in its final analysis 702 patients scheduled for elective major non-cardiac surgery in 12 medical centers in 5 countries (France, Germany, Italy, Spain, UK). It is the first multicenter registry involving a predictive monitoring technology, establishing a large, prospectively collected data base on hypotension management in patients having non-cardiac surgery. All patients had intraarterial blood pressure monitoring with an arterial catheter and intraoperative Acumen HPI software.

Both the duration and severity of intraoperative hypotension are associated with

postoperative complications. The primary endpoint of this registry, therefore, was intraoperative hypotension quantified using the time-weighted average mean arterial pressure (MAP) <65 mmHg. Secondary endpoints included the proportion of patients with at least one ≥1-min-episode of a MAP <65 mmHg, and the number of ≥1-min-episodes of a MAP <65 mmHg.

Between September 2021 and May 2022, 749 patients were enrolled in the registry and 702 included in the final analysis. The median time-weighted average MAP <65 mmHg was 0.03 (0.00, 0.20) mmHg. 285 patients (41%) had no ≥1-min-episode of a MAP <65 mmHg – 417 patients (59%) had at least one. The median number of ≥1-min-episodes of a MAP <65 mmHg was 1 (0, 3).

In addition, although the study was not powered for this outcome, the incidence of acute kidney injury was at the lower end of what is reported in patients having major non-cardiac surgery.

In Europe, of the 2.5 million patients undergoing high-risk surgery annually, one in four develops serious postoperative complications^1,2. Throughout the hospital patient journey, anaesthetists and intensivists need to analyse large amounts of data to make life-critical decisions for patients. One example is critical drops in blood pressure known as hypotension. Intraoperative hypotension is common in patients having non-cardiac surgery under general anaesthesia³. Intraoperative hypotension is associated with increased mortality and major postoperative complications (myocardial injury, acute kidney injury)^(4-8).

These postoperative complications come with a significant cost burden for healthcare systems as they are linked with rehospitalisations and increased morbidity.⁹

“Avoiding intraoperative hypotension is a complex task for anesthetists. Current hypotension treatment is mainly reactive, sometimes only being initiated after the blood pressure has already dropped below safe levels”, explains Prof. Bernd Saugel (Hamburg, Germany).

Edwards Lifesciences has developed the Acumen HPI software, which provides clinicians with information regarding the likelihood that a patient will develop hypotension. Based on an algorithm that calculates data from hemodynamic monitoring in perioperative management, it leverages predictive analytics to alert clinicians of potential blood pressure drops before they occur.

“Predictive hemodynamic monitoring may be a promising approach to help clinicians better manage hypotension. It is intriguing to investigate innovations that can support clinicians in clinical decision making and potentially improve quality of care,” comments Prof. Bernd Saugel (Hamburg, Germany).

“The consequences of the COVID-19 pandemic have drastically accelerated the need for solutions that improve patient safety and outcomes, reduce hospital length of stay and increase hospital efficiencies. The results of the EU-HYPROTECT registry are promising and demonstrate the need to better monitor hypotension in the perioperative pathway. Improving patient safety and outcomes is our ultimate goal and we believe the use of predictive monitoring can help achieve this.” comments Pr Thomas Scheeren, Senior Director Medical Affairs EMEACLA at Edwards Lifesciences. 

The full results of the EU-HYPROTECT registry were published in the British Journal of Anaesthesia and can be consulted on https://www.bjaopen.org/article/S2772-6096(23)00019-9/fulltext

About Edwards Lifesciences

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

Edwards, Edwards Lifesciences, the stylized E logo, Acumen, Acumen HPI, HPI and Hypotension Prediction Index are trademarks of Edwards Lifesciences Corporation and its affiliates. All other trademarks are the property of their respective owners. This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.